Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

@article{Balash2017MedicalCI,
  title={Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience},
  author={Y. Balash and Lihi Bar-Lev Schleider and A. Korczyn and H. Shabtai and J. Knaani and A. Rosenberg and Y. Baruch and R. Djaldetti and Nir Giladi and T. Gurevich},
  journal={Clinical Neuropharmacology},
  year={2017},
  volume={40},
  pages={268–272}
}
  • Y. Balash, Lihi Bar-Lev Schleider, +7 authors T. Gurevich
  • Published 2017
  • Medicine
  • Clinical Neuropharmacology
  • Background The use of medical cannabis (MC) is controversial. [...] Key Method Results Forty-seven nondemented patients with PD (40 men) participated. Their mean age was 64.2 ± 10.8 years, mean disease duration was 10.8 ± 8.3 years, median Hoehn and Yahr (H&Y) was stage III. The duration of MC use was 19.1 ± 17.0 months, and the mean daily dose was 0.9 ± 0.5 g. The delivery of MC was mainly by smoking cigarettes (38 cases, 80.9%). Effect size (r2) improvement for falls was 0.89, 0.73 for pain relief, 0.64 for…Expand Abstract
    24 Citations
    The effects of Cannabis on hallucinations in Parkinson's disease patients
    A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age
    • 9
    • PDF
    Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
    • 11
    Medical cannabis in the UK: From principle to practice

    References

    SHOWING 1-10 OF 26 REFERENCES
    Cannabis for dyskinesia in Parkinson disease
    • 129
    Discriminating the effects of Cannabis sativa and Cannabis indica: a web survey of medical cannabis users.
    • 30
    Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms
    • 112
    • Highly Influential
    • PDF
    Marijuana for parkinsonian tremor.
    • 64
    • PDF
    [MEDICAL CANNABIS].
    • 22
    • PDF